Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme

Ensartinib (X-396) is a promising tyrosine kinase inhibitor currently undergoing advanced clinical evaluation for the treatment of non-small cell lung cancer. In this work, we investigate possible interactions of this promising drug candidate with ATP-binding cassette (ABC) drug efflux transporters...

Descripción completa

Detalles Bibliográficos
Autores principales: Vagiannis, Dimitrios, Novotna, Eva, Skarka, Adam, Kammerer, Sarah, Küpper, Jan-Heiner, Chen, Si, Guo, Lei, Staud, Frantisek, Hofman, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226045/
https://www.ncbi.nlm.nih.gov/pubmed/32231067
http://dx.doi.org/10.3390/cancers12040813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226045/
https://www.ncbi.nlm.nih.gov/pubmed/32231067
http://dx.doi.org/10.3390/cancers12040813

Ejemplares similares